Share
Are you looking to domesticate wild organisms?  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Hi ,

SynBioBeta is growing! Lead the content strategy for our organization, serving a growing international community of over 100,000 synthetic biologists, entrepreneurs and investors. Check out the job posting for Director of Content here.

Are you looking to domesticate wild organisms? Are there any organisms or molecules that you've given up on? Well, you should meet our newest sponsor, MicroByre. Sarah Richardson, their CEO, is going to be speaking at SynBioBeta 2023 about how they are domesticating bacteria to create new chemicals, exploit new metabolisms, and deploy less expensive feedstocks to make biotechnology less expensive. Joel Pastore, their new Vice President of Business Development, has worked at Cargill, and you can also meet him at SynBioBeta.

  • Leaps by Bayer launches Chapter III: Leap Forward, which shows us that a breakthrough is never just a leap in isolation. "It requires joining forces with others who dare to push difficult boundaries," according to Juergen Eckhardt. In the third film of their Chapter trilogy, Leaps brought together the world-record holding kite surfer Olivia Jenkins and a team led by scientist and Olympic weather coach Dr. Alicia Ageno on the remote Pacific Island of Samoa. "We not only witness a literal journey toward tomorrow, but we also gain a deeper understanding of why every leap in science urgently matters to humankind," says Eckhardt.
  • Can a desktop DNA printer stomp out the next pandemic? Imagine you could print DNA on your desktop. What would that enable you to do? Labs in remote locations could print out mRNA vaccines to fight emerging epidemics and develop cell and gene therapies.Telesis Bio is bringing that vision to reality – with their desktop BioXp platform that can synthesize DNA and RNA on demand.
  • Mark Cuban has taken on pharma and forever disrupted healthcare in America. In an industry where 90% of drugs fail, the 10% that enter the marketplace are priced sky-high to ensure profitability. Could a model where drugs are sold at 15% markup from the wholesale price ever work?

Mark Cuban speaking at Life Itself with Sanjay Gupta. Photo: Marc Hodosh

  • This biotech company’s goal is to have a plant-based American flag fly over the White House: Last week, Geno's CEO Christophe Schilling appeared before the U.S. Senate Committee to discuss policies to help advance biomanufacturing, including the $250M loan guarantee program and the BioPreferred initiative. Geno is one of the first synthetic biology companies that is making a substantial impact on sustainability with their products like Brontide, bio-nylon, & bio-BDO.

Geno's CEO Christophe Schilling

  • Could gene editing make cosmetics more sustainable? The cosmetics business has exploited natural resources for centuries. With consumers now demanding more sustainable products, gene-editing technology could give the industry a makeover—and make cosmetics cheaper.

SynBioBeta 2023 speakers:

Hear what our speakers have to say at SynBioBeta 2023. Get the inside scoop on where the biggest opportunities are – get your ticket TODAY!

  • Ana Bernardo-Gancedo is an Analyst at Amadeus Capital Partners. She has advocated for multiple investments in the life sciences and synbio sectors, including Nuclera, Oxford Nanopore, Ori Biotech and Constructive Bio.

  • Mark Murcko is a Board Member and Strategic Advisor of Octant Bio, a therapeutics company building drugs that match the complexity of human diseases.

  • Stef van Grieken is the co-founder and CEO of Cradle, a startup that aims to make it easier to engineer proteins with the help of machine learning.

  • Avencia Sanchez-Mejias is the CEO and Co-founder of Integra Therapeutics, who is developing new gene writing tools that help improve the scope, efficiency and safety of advanced therapies.

Covid-19 news

New products

Partnerships

In other news:

Regards,
John

---

John Cumbers
Founder, SynBioBeta

Who's hiring?

View in Browser »

Like our Digest? Please feel free to share with friends, family, and co-workers!


SynBioBeta, LLC
3559 Mount Diablo Boulevard #2, Lafayette, CA 94549

info@synbiobeta.com

If you no longer wish to receive our emails, you can unsubscribe here.
Modify Your Email Preferences


Email Marketing by ActiveCampaign